Patents by Inventor Stewart D. Lyman

Stewart D. Lyman has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Human TSLP DNA and polypeptides
    Patent number: 6555520
    Abstract: The invention is directed to purified and isolated novel TSLP polypeptides, the nucleic acids encoding such polypeptides, processes for production of recombinant forms of such polypeptides, antibodies generated against these polypeptides, fragmented peptides derived from these polypeptides, and the uses of the above.
    Type: Grant
    Filed: May 9, 2001
    Date of Patent: April 29, 2003
    Assignee: Immunex Corporation
    Inventors: John E. Sims, Stewart D. Lyman, Hilary J. McKenna, Allison P. Armstrong
  • Antibodies against flt3-ligand
    Publication number: 20020160004
    Abstract: Ligands for flt3 receptors capable of transducing self-renewal signals to regulate the growth, proliferation or differentiation of progenitor cells and stem cells are disclosed. The invention is directed to anti-flt3-L antibodies and enzyme-linked immunosorbent assays comprising such antibodies.
    Type: Application
    Filed: March 13, 2002
    Publication date: October 31, 2002
    Inventors: Stewart D. Lyman, M. Patricia Beckmann
  • Human TSLP DNA and polypeptides
    Publication number: 20020146819
    Abstract: The invention is directed to purified and isolated novel TSLP polypeptides, the nucleic acids encoding such polypeptides, processes for production of recombinant forms of such polypeptides, antibodies generated against these polypeptides, fragmented peptides derived from these polypeptides, and the uses of the above.
    Type: Application
    Filed: May 9, 2001
    Publication date: October 10, 2002
    Inventors: John E. Sims, Stewart D. Lyman, Hilary J. McKenna, Allison P. Armstrong
  • Ligand for CD7 and methods for use thereof
    Publication number: 20020141999
    Abstract: The invention relates to CD7 and the discovery of its cognate ligand, the K12 protein, and the identification and cloning of polynucletides that encode the murine homolog of the human K12. Also disclosed are methods of screening candidate molecules to determine potential antagonists and agonists of the interaction between CD7 and K12. The use of the antagonists and agonists, including soluble K12 proteins, as therapeutics to treat diseases modulated by CD7 are also disclosed.
    Type: Application
    Filed: November 27, 2001
    Publication date: October 3, 2002
    Inventors: Stewart D. Lyman, William C. Fanslow
  • Ligands for flt3 receptors
    Publication number: 20020107365
    Abstract: Ligands for flt3 receptors capable of transducing self-renewal signals to regulate the growth, proliferation or differentiation of progenitor cells and stem cells are disclosed. The invention is directed to flt3-L as an isolated protein, the DNA encoding the flt3-L, host cells transfected with cDNAs encoding flt3-L, compositions comprising flt3-L, methods of improving gene transfer to a mammal using flt3-L, and methods of improving transplantations using fit3-L. Flt3 -L finds use in treating patients with anemia, AIDS and various cancers.
    Type: Application
    Filed: October 25, 2001
    Publication date: August 8, 2002
    Inventors: Stewart D. Lyman, M. Patricia Beckmann
  • DENDRITIC CELL STIMULATORY FACTOR
    Publication number: 20020034517
    Abstract: Flt3-ligand can be used to generate large numbers of dendritic cells from hematopoietic progenitor and stem cells. Flt3-ligand can be used to augment immune responses in vivo, and expand dendritic cells ex vivo. Such dendritic cells can then be used to present tumor, viral or other antigens to naive T cells, can be useful as vaccine adjuvants.
    Type: Application
    Filed: November 23, 1999
    Publication date: March 21, 2002
    Inventors: KENNETH BRASEL, STEWART D. LYMAN, EUGENE MARASKOVSKY, HILARY J MCKENNA, DAVID H. LYNCH, CHARLES R. MALISZEWSKI
  • Methods of using Flt-3 ligand for exogenous gene transfer
    Patent number: 6190655
    Abstract: Ligands for flt3 receptors capable of transducing self-renewal signals to regulate the growth, proliferation or differentiation of progenitor cells and stem cells are disclosed. The invention is directed to flt3-L as an isolated protein, the DNA encoding the flt3-L, host cells transfected with cDNAs encoding flt3-L, compositions comprising flt3-L, methods of improving gene transfer to a mammal using flt3-L, and methods of improving transplantations using flt3-L. Flt3-L finds use in treating patients with anemia, AIDS and various cancers.
    Type: Grant
    Filed: September 25, 1998
    Date of Patent: February 20, 2001
    Assignee: Immunex Corporation
    Inventors: Stewart D. Lyman, M. Patricia Beckmann
  • Methods of stimulating hematopoietic cells with flt3-ligand
    Patent number: 5843423
    Abstract: Ligands for flt3 receptors capable of transducing self-renewal signals to regulate the growth, proliferation or differentiation of progenitor cells and stem cells are disclosed. The invention is directed to flt3-L as an isolated protein, the DNA encoding the flt3-L, host cells transfected with cDNAs encoding flt3-L, compositions comprising flt3-L, methods of improving gene transfer to a mammal using flt3-L, and methods of improving transplantations using flt3-L. Flt3-L finds use in treating patients with anemia, AIDS and various cancers.
    Type: Grant
    Filed: December 18, 1997
    Date of Patent: December 1, 1998
    Assignee: Immunex Corporation
    Inventors: Stewart D. Lyman, M. Patricia Beckmann
  • Ligands for flt3 receptors
    Patent number: 5554512
    Abstract: Ligands for flt3 receptors capable of transducing self-renewal signals to regulate the growth, proliferation or differentiation of progenitor cells and stem cells are disclosed. The invention is directed to flt3-L as an isolated protein, the DNA encoding the flt3-L, host cells transfected with cDNAs encoding flt3-L, compositions comprising flt3-L, methods of improving gene transfer to a mammal using flt3-L, and methods of improving transplantations using flt3-L. Flt3-L finds use in treating patients with anemia, AIDS and various cancers.
    Type: Grant
    Filed: May 11, 1994
    Date of Patent: September 10, 1996
    Assignee: Immunex Corporation
    Inventors: Stewart D. Lyman, M. Patricia Beckmann